News

GlaxoSmithKline staff told not to publicise ineffectiveness of its drug

BMJ 2004; 328 doi: 10.1136/bmj.328.7437.422-a (Published 19 February 2004)
Cite this as: BMJ 2004;328:422.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David Spurgeon
  1. Quebec

    CMAJ (the journal of the Canadian Medical Association) has published details of an internal document from the drug company GlaxoSmithKline that advised its staff to withhold the findings of a clinical trial in 1998 showing that the antidepressant paroxetine had no benefit in treating adolescents.

    The association has publicised the document on its website in an early release of its Analysis column (www.cmaj.ca).

    Last year, the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular